EIRGENIX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 80.6 TWD | -0.86% |
|
-6.28% | -19.80% |
| Sales 2024 * | 2.06B 63.53M | Sales 2025 * | 2.73B 84.25M | Capitalization | 24.89B 769M |
|---|---|---|---|---|---|
| Net income 2024 * | 137M 4.23M | Net income 2025 * | 413M 12.76M | EV / Sales 2024 * | 9.54 x |
| Net cash position 2024 * | 5.29B 163M | Net cash position 2025 * | 5.26B 162M | EV / Sales 2025 * | 7.2 x |
| P/E ratio 2024 * |
181
x | P/E ratio 2025 * |
60.2
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.78% | ||
| 1 week | -5.47% | ||
| Current month | -6.55% | ||
| 1 month | -8.03% | ||
| 3 months | -14.96% | ||
| 6 months | -14.96% | ||
| Current year | -19.10% |
1 week
78.70
86.20
1 month
78.7089.00
Current year
78.70103.00
1 year
78.70129.50
3 years
71.60195.00
5 years
21.55195.00
10 years
21.55195.00
| Managers | Title | Age | Since |
|---|---|---|---|
Li Cheng Liu
CEO | Chief Executive Officer | - | 12-12-20 |
Hsiu Chuan Yang
DFI | Director of Finance/CFO | - | 16-05-02 |
Chih Jung Chang
COO | Chief Operating Officer | - | 13-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chih Lung Shen
BRD | Director/Board Member | 59 | 21-12-05 |
Cheng Yue Cheng
BRD | Director/Board Member | - | 13-06-13 |
Ming Hsien Chen
BRD | Director/Board Member | - | 16-09-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.49% | - | |
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-17 | 80.6 | -0.86% | 365 911 |
| 24-04-17 | 81.3 | +2.78% | 600,230 |
| 24-04-16 | 79.1 | -3.89% | 1,578,079 |
| 24-04-15 | 82.3 | -3.52% | 1,368,984 |
| 24-04-12 | 85.3 | -0.58% | 480,155 |
End-of-day quote Taipei Exchange, April 16, 2024
More quotes
EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
81.3
TWD
Average target price
132.5
TWD
Spread / Average Target
+62.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.10% | 766M | |
| -5.32% | 84.57B | |
| +2.11% | 39.93B | |
| -25.74% | 27.93B | |
| +52.72% | 24.21B | |
| -6.17% | 17.17B | |
| -31.09% | 13.93B | |
| -6.58% | 12.3B | |
| -16.04% | 11.84B | |
| -4.04% | 7.91B |
- Stock Market
- Equities
- 6589 Stock
